Pharmacological treatment of COPD - New evidence.

Chronic Obstructive Pulmonary Disease (COPD) is currently the 4th leading cause of death worldwide but is projected to be the 3rd leading cause of death by 2020. In Portugal, the estimated prevalence of COPD in the Lisbon region is 14.2%, and a large proportion of underdiagnosed disease has been detected. In 2016, a Portuguese panel of experts proposed pharmacological treatment approaches to COPD based on the evidence available at the time. However, given that the GOLD 2017 report introduced considerable changes to the 2016 version, and that new evidence has emerged regarding treatment options, these proposals need to be updated. Also, and based on several studies, the concept of Pre-GOLD patients, which has diagnostic, prognostic and therapeutic implications, is introduced, along with a proposed algorithm for the identification and treatment of these patients.

• Publication year

  2019

• Venue

  Pulmonology

• Publication date

  2019-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.pulmoe.2018.10.005PMID 30502972
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Making Sense of Triple Inhaled Therapy for COPD.

  2018cited by this paper
• Long‐Term Triple Therapy De‐escalation to Indacaterol/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double‐Blind, Triple‐Dummy Clinical Trial

  2018cited by this paper
• COPD: time to improve its taxonomy?

  2018cited by this paper
• Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial.

  2018cited by this paper
• Once‐Daily Single‐Inhaler Triple versus Dual Therapy in Patients with COPD

  2018cited by this paper
• Diagnostic Instability and Reversals of Chronic Obstructive Pulmonary Disease Diagnosis in Individuals with Mild to Moderate Airflow Obstruction

  2017cited by this paper
• Clinical Features of Smokers With Radiological Emphysema But Without Airway Limitation

  2017cited by this paper
• Eosinophilia, Frequent Exacerbations, and Steroid Response in Chronic Obstructive Pulmonary Disease.

  2017cited by this paper
• Blood Eosinophils and Response to Maintenance Chronic Obstructive Pulmonary Disease Treatment. Data from the FLAME Trial

  2017cited by this paper
• Optimal treatment sequence in COPD: Can a consensus be found?

  2016cited by this paper
• Treatment patterns in COPD patients newly diagnosed in primary care. A population-based study.

  2016cited by this paper
• Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD.

  2016cited by this paper
• Should the diagnosis of COPD be based on a single spirometry test?

  2016cited by this paper
• Effects of tiotropium + olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO® studies

  2016cited by this paper
• Clinical Significance of Symptoms in Smokers with Preserved Pulmonary Function.

  2016cited by this paper
• COPD control: Can a consensus be found?

  2016cited by this paper
• COPD: A stepwise or a hit hard approach?

  2016influential reference
• Smoking, Not COPD, as the Disease.

  2016cited by this paper
• Bronchodilator treatment for COPD in primary care of four Latin America countries: The multinational, cross-sectional, non-interventional PUMA study.

  2016cited by this paper
• LATE-BREAKING ABSTRACT: Indacaterol/glycopyrronium (IND/GLY) reduces the risk of exacerbations versus salmeterol/fluticasone (SFC) in moderate-to-very severe COPD patients irrespective of prior ICS/LABA/LAMA therapy: The FLAME study

  2016influential reference
• The Relationship Between 24-Hour Symptoms and COPD Exacerbations and Healthcare Resource Use: Results from an Observational Study (ASSESS)

  2016cited by this paper
• Acute Exacerbations and Lung Function Loss in Smokers with and without Chronic Obstructive Pulmonary Disease

  2016cited by this paper
• Effectiveness of Fluticasone Furoate-Vilanterol for COPD in Clinical Practice.

  2016cited by this paper
• Applying the wisdom of stepping down inhaled corticosteroids in patients with COPD: a proposed algorithm for clinical practice

  2015cited by this paper
• LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD

  2015cited by this paper
• Epidemiology, severity, and treatment of chronic obstructive pulmonary disease in the United Kingdom by GOLD 2013

  2015cited by this paper
• Instability in the COPD Diagnosis upon Repeat Testing Vary with the Definition of COPD

  2015cited by this paper
• The impact of treatment with indacaterol in patients with COPD: A post-hoc analysis according to GOLD 2011 categories A to D.

  2015cited by this paper
• Early impact of treatment with tiotropium, long-acting anticholinergic preparation, in patients with COPD – real-life experience from an observational study

  2015cited by this paper
• COPD: early diagnosis and treatment to slow disease progression

  2015cited by this paper
• Long‐acting muscarinic antagonist + long‐acting beta agonist versus long‐acting beta agonist + inhaled corticosteroid for COPD: A systematic review and meta‐analysis

  2015influential reference
• Clinical and Radiologic Disease in Smokers With Normal Spirometry.

  2015cited by this paper
• COPD: early diagnosis and treatment to slow disease progression

  2015cited by this paper
• Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study.

  2013cited by this paper
• Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study.

  2013cited by this paper
• Chronic obstructive pulmonary disease prevalence in Lisbon, Portugal: the burden of obstructive lung disease study.

  2013cited by this paper
• Comparisons of health status scores with MRC grades in COPD: implications for the GOLD 2011 classification

  2012cited by this paper
• Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease

  2012cited by this paper
• Tiotropium versus salmeterol for the prevention of exacerbations of COPD.

  2011cited by this paper
• Creating scenarios of the impact of copd and their relationship to copd assessment test (CAT™) scores

  2011cited by this paper
• Susceptibility to exacerbation in chronic obstructive pulmonary disease.

  2010cited by this paper
• Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary.

  2007cited by this paper
• Global Initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease

  2006cited by this paper
• International Journal of Copd Dovepress Copd: It Is Time to Change!

  year unknowncited by this paper

• Effectiveness of Home-based Pulmonary Rehabilitation on Exercise Capacity and Quality of Life in COPD Patients: A Prospective Study from Himachal Pradesh, India

  2026cites this paper
• Experience of Using Electronic Inhaler Monitoring Devices for Patients With Chronic Obstructive Pulmonary Disease or Asthma: Systematic Review of Qualitative Studies

  2025cites this paper
• Use of the Serum Level of Cholinesterase as a Prognostic Marker of Nonfatal Clinical Outcomes in Patients Hospitalized with Acute Exacerbations of Chronic Obstructive Pulmonary Disease

  2024cites this paper
• Inhalation of patchouli essential oil alleviates airway inflammation in cigarette smoke-induced COPD mice

  2024cites this paper
• In silico analysis of airflow in a single path configuration of the pulmonary tree

  2024cites this paper
• Matrix Metalloproteinases in Chronic Obstructive Pulmonary Disease

  2023cites this paper
• Educational Interventions in Immigrants for Asthma and COPD: A Systematic Review

  2023cites this paper
• Chronic obstructive pulmonary disease exacerbations' management in Portuguese hospitals - EvaluateCOPDpt, a multicentre, observational, prospective study.

  2022cites this paper
• Artesunate ameliorates cigarette smoke-induced airway remodelling via PPAR-γ/TGF-β1/Smad2/3 signalling pathway

  2021cites this paper
• Cough: A Practical and Multifaceted Approach to Diagnosis and Management.

  2020cites this paper
• CUL1-Mediated Organelle Fission Pathway Inhibits the Development of Chronic Obstructive Pulmonary Disease

  2020cites this paper
• The effects of 1α,25-dihydroxyvitamin D3 on alveolar repair and bone mass in adiponectin-deficient mice.

  2020cites this paper
• Therapeutic Targeting of MMP-12 for the Treatment of Chronic Obstructive Pulmonary Disease.

  2020cites this paper
• Method for Pulmonary Administration Using Negative Pressure Generated by Inspiration in Mice

  2020cites this paper